Dalian BIO-CHEM Company Limited

Established in 2003 and headquartered in Dalian, China, Dalian BIO-CHEM Company Limited specializes in the manufacture and distribution of antimicrobial agents, specifically bactericides, antiseptics, and fungicides. These products serve a broad spectrum of industrial sectors across continents, including Europe, North and South America, the Middle East, Africa, and Asia. The company's offerings perform various crucial functions: they act as disinfectants and effective algaecides for water treatment systems in industries like petrochemicals, power generation, central air conditioning, and industrial cooling. Additionally, they provide corrosion protection within aqueous systems, found in products such as emulsions, mineral slurries, pigment dispersions, adhesives, tackifiers, metalworking fluids, and cosmetics. Their solutions also extend to the aqueous formulations used in leather, paints, coatings, textiles, and dyeing processes. Furthermore, Dalian BIO-CHEM's products combat mildew and algae, and the company offers a specialized dry film preservative tailored for paints and coatings.

Dalian BIO-CHEM Company Limited trades as 603360.SS on SHH. The company is classified in Basic Materials / Chemicals - Specialty and reports in CNY.

The current profile places the business in Chemicals - Specialty. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Dalian BIO-CHEM Company Limited can be compared against peers such as Sichuan New Energy Power Company Limited, Hengyi Petrochemical Co., Ltd., Sichuan Yahua Industrial Group Co., Ltd., Shandong Sinocera Functional Material Co., Ltd., Weihai Guangwei Composites Co., Ltd., POCO Holding Co., Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $14.13B, beta of 0.09, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

603360.SS currently shows total debt of N/A and beta of 0.09. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.biofc.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.